bluebird bio, Inc. (BLUE) Position Reduced by First Light Asset Management LLC
First Light Asset Management LLC decreased its position in bluebird bio, Inc. (NASDAQ:BLUE) by 31.4% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 33,780 shares of the biotechnology company’s stock after selling 15,490 shares during the period. First Light Asset Management LLC owned about 0.07% of bluebird bio worth $3,549,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the stock. Tudor Investment Corp ET AL acquired a new position in bluebird bio in the 2nd quarter worth approximately $436,000. QS Investors LLC boosted its stake in bluebird bio by 70.7% in the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares during the period. Voya Investment Management LLC boosted its stake in bluebird bio by 1,251.6% in the 2nd quarter. Voya Investment Management LLC now owns 217,398 shares of the biotechnology company’s stock worth $22,837,000 after purchasing an additional 201,313 shares during the period. Dimensional Fund Advisors LP boosted its stake in bluebird bio by 25.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 106,189 shares of the biotechnology company’s stock worth $11,158,000 after purchasing an additional 21,228 shares during the period. Finally, Teachers Retirement System of The State of Kentucky boosted its stake in bluebird bio by 8.2% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 32,587 shares of the biotechnology company’s stock worth $3,423,000 after purchasing an additional 2,477 shares during the period.
In other bluebird bio news, insider Eric Sullivan sold 861 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $93.83, for a total transaction of $80,787.63. Following the sale, the insider now directly owns 5,924 shares of the company’s stock, valued at $555,848.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Davidson sold 3,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $92.37, for a total transaction of $277,110.00. Following the sale, the insider now directly owns 18,977 shares in the company, valued at $1,752,905.49. The disclosure for this sale can be found here. Insiders have sold 133,829 shares of company stock valued at $16,006,899 in the last 90 days. 3.90% of the stock is currently owned by corporate insiders.
Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded down 2.69% on Friday, reaching $137.35. 1,215,502 shares of the company traded hands. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $143.50. The stock’s market cap is $6.26 billion. The stock has a 50 day moving average of $108.37 and a 200 day moving average of $97.10.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The business had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same quarter in the previous year, the company posted ($1.59) EPS. The business’s revenue for the quarter was up 977.4% compared to the same quarter last year. On average, analysts expect that bluebird bio, Inc. will post ($6.84) earnings per share for the current year.
BLUE has been the subject of a number of research reports. Cantor Fitzgerald set a $39.00 target price on shares of bluebird bio and gave the company a “sell” rating in a research note on Saturday, June 24th. Jefferies Group LLC reissued a “buy” rating on shares of bluebird bio in a research note on Thursday, July 6th. Sanford C. Bernstein initiated coverage on shares of bluebird bio in a research note on Thursday, July 27th. They set a “market perform” rating and a $109.00 target price for the company. BMO Capital Markets reissued a “buy” rating and set a $108.00 target price on shares of bluebird bio in a research note on Friday, August 4th. Finally, BidaskClub raised shares of bluebird bio from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $107.86.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.